Education
About Us
Working with TipRanks
Follow Us
iCAD Inc (ICAD)
:ICAD
ICAD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.18 - $3.78
Previous CloseN/A
Volume130.78K
Average Volume (3M)388.83K
Market Cap
$59.18M
Enterprise Value$31.38M
Total Cash (Recent Filing)$12.19M
Total Debt (Recent Filing)$13.10M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
May 19, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding26,540,030
10 Day Avg. Volume296,403
30 Day Avg. Volume388,833
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.12
Price to Cash Flow (P/CF)-9.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda-6.30
Forecast
1Y Price Target
$3.00Price Target Upside34.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
iCAD News
PremiumCompany Announcements
iCAD Inc. Earnings Call Highlights Growth and ChallengesPremiumCompany Announcements
iCAD, Inc. Reports Strong Revenue Growth Amid SaaS Transition
PremiumPre-Earnings
Is ICAD a Buy, Before Earnings?PremiumCompany Announcements
iCAD, Inc. Reports Growth in ARR and Revenue---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceICAD reported preliminary Q4 revenue beating consensus and estimates.
International ExpansionICAD has entered into new global distribution partnerships for ProFound Cloud in multiple countries, indicating international expansion.
Product ApprovalProFound Detection v4.0, which was cleared by the FDA, has shown even better accuracy in real-world practice than in clinical studies.
Bears Say
Revenue ConcernsThere is an expectation of near-term lumpiness because of the lower upfront revenue from the transition to a recurring model.
UnderperformanceICAD reported Q3 revenue of $4.2M, below consensus of $4.5M and estimates of $4.8M.
---
Ownership Overview
5.07% Insiders
11.46% Mutual Funds
7.88% Other Institutional Investors
71.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ICAD FAQ
What was iCAD Inc’s price range in the past 12 months?
iCAD Inc lowest stock price was $1.18 and its highest was $3.78 in the past 12 months.
What is iCAD Inc’s market cap?
iCAD Inc’s market cap is $59.18M.
When is iCAD Inc’s upcoming earnings report date?
iCAD Inc’s upcoming earnings report date is May 19, 2025 which is in 56 days.
How were iCAD Inc’s earnings last quarter?
iCAD Inc released its earnings results on Mar 19, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.052 by $0.022.
Is iCAD Inc overvalued?
According to Wall Street analysts iCAD Inc’s price is currently Undervalued.
Does iCAD Inc pay dividends?
iCAD Inc does not currently pay dividends.
What is iCAD Inc’s EPS estimate?
iCAD Inc’s EPS estimate is -0.06.
How many shares outstanding does iCAD Inc have?
iCAD Inc has 26,540,030 shares outstanding.
What happened to iCAD Inc’s price movement after its last earnings report?
iCAD Inc reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.052. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of iCAD Inc?
Currently, no hedge funds are holding shares in ICAD
---
iCAD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (34.53% Upside)
$3.00 (34.53% Upside)
Blogger Sentiment
Bullish
ICAD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 41.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
-18.09%
Trailing 12-Months
Asset Growth
-9.36%
Trailing 12-Months
Company Description
iCAD Inc
iCAD, Inc. is a medical technology company that provides innovative cancer detection and therapy solutions. The company operates in the healthcare sector and is known for its advanced image analysis and workflow solutions that enable earlier cancer detection and improve patient outcomes. iCAD's core products include artificial intelligence-driven solutions for mammography and breast cancer detection, as well as radiation therapy solutions for cancer treatment.
---
ICAD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for iCAD with strong revenue growth, successful SaaS transition, and significant advancements in AI technology and global partnerships. However, financial challenges such as increased operating expenses and net losses are present due to strategic investments and the SaaS transition.Read More>---
ICAD Stock 12 Month Forecast
Average Price Target
$3.00
▲(34.53% Upside)
Technical Analysis
Best Analysts Covering ICAD
1 Year
1 Year Success Rate
7/24 ratings generated profit
1 Year Average Return
-28.11%
reiterated a buy rating 6 days ago
Copying Marie Thibault's trades and holding each position for 1 Year would result in 29.17% of your transactions generating a profit, with an average return of -28.11% per trade.
---